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Abstract The age of lung transplant recipients is steadily in-
creasing. Older donors are more frequently considered. The
risk factors associated with advanced age in lung transplanta-
tion warrant discussion to ensure optimal outcomes in this
complex endeavor. This report provides a summary of the
pertinent topics and available evidence.
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Life expectancy is rising in many societies. A growing pro-
portion of the population is over 65 years of age [1, 2]. As a
consequence, older patients are referred for consideration for
lung transplantation [3]. Prognostic and symptomatic indica-
tions exist for this established treatment option in selected
candidates with end-stage lung diseases. Lung transplantation,
however, remains a complex endeavor and is offered for a
wide range of ages with associated risks (see ISHLT data
graphic/Fig. 1).
This review provides summary and context for factors con-
tributing to the discussion. Relevant definitions of Bage^ are
offered. The limitations of currently available evidence are
recognized. Analyses of registry data and other most relevant
information including single center studies and retrospective
cohorts are reviewed. The recipient age-related concerns are
then reviewed. Additionally, we discuss the donor age-related
allograft problems. Finally, a pragmatic approach to utilize
such advanced aged donor lungs in appropriate recipients is
considered.
Background
Age may be defined as a chronological entity or a biological
concept. The numerical value ascribed to a person’s age may be
a vague indicator, but is frequently seen as insufficient to allow
judgment regarding general health status. There is a lack of
qualitative understanding in order to allow meaningful care de-
cisions. Biological age, on the other hand, is a complex concept.
It entails cell biological processes that are not easily quantified.
Age related functionality of organisms has a molecular bases.
Fundamentals such as a patient’s tissue regenerative capacity, for
example, are not currently measurable. For decisions in clinical
practice, it is frequently necessary to compliment the numeric
age with valid criteria for functional age.
Assessments of various factors indicative of adequacy of
lung transplantation are needed in each potential recipient.
Candidates over the age of 70 years are not routinely referred
for workup for lung transplantation. Arbitrary restrictions ex-
ist for most programs. The conventional definition offered for
Belderly^ patients is older than 65 years of age (Fig. 2). United
Network of Organ Sharing (UNOS) and the International
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Society of Heart and Lung Transplantation (ISHLT) offer per-
tinent registry data [4, 5]. These suggest a steady shift toward
older recipients over the last decade. Several centers have
reported successful transplantation in patients with markedly
more advanced ages.
Compared to other solid organ transplants, lung transplan-
tation outcomes are recognized as still suboptimal [6••]. Yet, a
liberation of inclusion criteria has occurred over the last decade
[7••]. Outcomes observed, in turn, ultimately influence the al-
location of allografts. This is particularly pertinent in view of
the persistent shortage of adequate donor lungs. The appropri-
ateness of lung transplantation at older ages remains a matter of
debate (Fig. 1). Age, therefore, has become a focus of concern
in many programs. Although not unique to lung
transplantation, both recipient age-related challenges and donor
age-associated factors are frequently under intense scrutiny.
Phenomena related to aging
It is generally agreed that the numeric age of some patients
may not reflect their Bbiological^ age or performance status.
Determining age in biological systems, however, is a complex
task. Even theoretical considerations are multifaceted. Four
related phenomena have to be considered: the process of ag-
ing, the determinants of longevity, age-associated diseases
encountered, and death per se [8]. The application of biolog-
ical aging to the context of lung transplantation needs to ac-
knowledge multiple clinical confounders and nonmedical life-
time limitations that pertain to individual patients.
A distinct set of genetic disorders associated with DNA
repair mechanisms provided evidence regarding the need of
functional genome maintenance during the aging process [9].
Bio-gerontologists have specified the determinants of aging.
These are not simply driven by genetic factors. Ageing is the
result of the Bloss of molecular fidelity^ and ensuing cellular
and metabolic dysfunction [10, 11]. The concept of antagonis-
tic pleiotropy describes the beneficial role of particular genes
early in life at the expense of inducing Baging^ later in life
[12]. Telomere changes are an area of intense research interest.
Phenotypical consequences of aging, however, may not al-
ways be visible. In turn, inherited dysfunction or mutations
may affect telomerases without correlation of chronological
age [13].
External, i.e., environmental, triggers impact cellular regu-
lation and immunogenic phenotype changes. The sum of these
molecular processes leads to cellular and organismal senes-
cence. Additionally, stress response research provides new
Fig. 1 Adult lung transplants. Survival by age group (transplants 1990–2011). Modified from ISHLT Registry [3]. http://www.ishlt.org/registries/slides.
asp?slides=heartLungRegistry
Fig. 2 Number of persons 65 years of age or older. 1900–2060 [4]. U.S
Census Bureau, Population Estimates and Projections; http://www.aoa.acl.
gov/Aging_Statistics/Profile/2014/2.aspx. Accessed July 6, 2015
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insights into the profound alterations of normally phylogenet-
ically preserved biochemical signaling pathways [14]. The
example of the live-span shortening effect of excessive caloric
intake and other specific nutritional deficits has been well
described. These are cumulative in the process of ageing due
to the metabolic disorders caused.
The process of ageing related general physiologic changes
have been subject to considerable research efforts. Regarding
lung transplant candidates, the pulmonary manifestations and
systemic performance are of primary concern. Pulmonaryman-
ifestations of advancing age may aggravate any underlying
respiratory disease process. The net effect may be that earlier
referral for lung transplant evaluation is required. Specifically,
reduced pulmonary elasticity and dependent zone airway clo-
sures are likely in the elderly. In addition, chest wall stiffness
and loss of muscle mass add restrictive elements to the respira-
tory impairment. Physiological correlates include a reduced
forced expiratory volume (FEV1) and increased residual vol-
ume, a decline in vital capacity as well as total lung capacity.
Chest wall restriction and body mass index-related issues
would then affect the recipient in the post-transplant phase even
in the presence of a functional allograft [15, 16].
Other aging-related cellular adaptations have a more wide-
ranging impact. Mitochondrial dysfunction and reduced respi-
ratory metabolism with increased deleterious effects of reactive
oxygen radicals develop. Multiple alterations of the immune
system have been documented in the elderly. A decline of the
adaptive immune responses and specific changes of the innate
immune-system are well documented. Cellular immunity may
be affected by reduced T cell subpopulations, impaired B cell
generation, and non-organ-specific auto-antibody formation
[17]. Susceptibility to certain pathogens has been demonstrated
and hyper-reactivity of airways may develop.
Age-related specific diseases then add to the burden with
individual end-organ manifestations including central nervous
system and neuro-muscular and degenerative impairment. The
resulting net effect of markedly reduced physiological reserve
may not be apparent until a response to critical illness stressors
is required. Therefore, a plethora of age-related possible comor-
bidities must be considered and actively investigated in elderly
candidates for transplantation. Some patients will present with
absolute contraindications defined for most lung transplant
programs, due to excessive perioperative risks perceived and
the ability to recover adequately post-operatively (Table 1).
Other age-related disease processes are clearly identifiable with
screening and manageable with adequate specialist care sys-
tems in place. As the incidence of cancer increases with age,
evaluation for specific risk factors and application of screening
protocols for the most common malignancies is an essential
part of the assessment of elderly candidates for potential lung
transplantation.
Additional concerns implicit in caring for elderly patients
are the risk of failure to thrive and other systemic comorbid-
ities difficult to reverse [18]. These include anorexia of aging
and relative cognitive impairment that require detailed clinical
assessment and at times specialist evaluation for underlying
causes. Similar to general frailty, these entities are hard to
quantify. They demand clinical acuity and judgment in the
absence of reliable biomarkers.
Lung transplantation in the elderly
Life expectancy varies among societies and socioeconomic
circumstances. Currently, expected remaining years of life in
the US for a person reaching the age of 65 is 17.9 years for
males and 20.5 years for females [19]. Lung transplantation
survival rates are frequently reported for multiple age groups.
National survival rate averages reported for lung transplanta-
tion in the US by UNOS are 82 % at 1 year, 65 % at 3 years,
and 51 % at 5 years, respectively. The primary motivation in
lung transplants is to improve the 1-year mortality observed
due to their underlying respiratory disease. Few elderly recip-
ients, however, will have a fully restored Blife expectancy .^ It
is therefore critical to understand each individual’s expecta-
tions in life and consider the symptomatic benefit for most of
these patients undergoing lung transplantation.
Despite the chronological continuum, registries report out-
comes observed after lung transplantation in arbitrarily select-
ed age categories. Such analysis often considers older recipi-
ents (>60 years of age and separately > 65 years). The ISHLT
registry and UNOS data provide such retrospective informa-
tion regarding transplant rates and survival outcomes in these
cohorts [5, 19]. This cannot include biological variances of
Table 1 Examples for age-
related comorbidities Possible age-related comorbidities in older lung transplant candidates
Systemic disease Malignancies, hypertension, cardiovascular, diabetes mellitus,
nutritional deficits, falls, and injuries
CNS disease Memory impairment, CVA, Parkinson’s disease hearing loss,
vision issues, sleep disorders
End-organ disease Coronary artery disease, thyroid disease, urinary disorders,
arthritis, osteoporosis, GI disorders, pressure ulcers
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patients at different ages and has to be seen as general indica-
tors rather than meaningful for individual patient assessment.
The age of recipients, when assessed according to the era of
lung transplantation in the ISHLT registry, also showed a
marked increase over time for 60–65- and >65-year-old recip-
ients [20••]. This trend of increasing median age for lung
transplant candidates has not been affected by implementation
of the Lung Allocation Score (LAS) in the US [21]. The pro-
portion of the 60–69-year-old recipients in particular has
steadily increased over the last 15 years according to UNOS
2014 data.
Single-center reviews provided limited evidence for sur-
vival outcomes in Bolder^ patient cohorts. These studies used
variable age cutoffs and are not directly comparable with
meta-analysis [22]. Notable in some of these cohorts are the
higher incidence of lethal infective complications in such
older recipients. Reviewing the complication rates of elderly
recipients, Tomascek et al. reported specific patient character-
istics associated with impaired outcomes in a single center
review. These included postoperative complications, length
of stay, achieved FEV1, and development of BOS at 1 year.
BMI was identified to impact overall complication rates in
their cohort older than 60 years at time of transplantation
[23]. Body composition and frailty have not been considered
in these reviews. No useful biomarkers or surrogate parame-
ters were available at the time of these retrospective studies.
A report reviewing available SRTR data indicates that 1-
year survival for septuagenarians in lung transplantation is
significantly worse when compared with 60–69-year-old re-
cipients in the cohort prior to 2005; (57 vs. 76 % 1-year sur-
vival, log rank p = 0.01) [24]. Three- and 5-year survival was
noted to be significantly less for elderly lung transplant recip-
ients. There appears to have been an improvement of survival
in septuagenarians since the LAS inception in the USA
(Fig. 3). This may be manifest despite increased proportion
of idiopathic pulmonary fibrosis in this cohort. The cohort
comprised 225 recipients with an observed one-year survival
of 79%. Due to their relative improvement, advanced age was
not considered to be an Babsolute^ contraindication [24].
A comparison of older (defined as >60 years of age) to
younger recipients in the Toronto Lung Transplant program
published in 2007 showed a marked 1-year survival difference
(60 vs. 86%). A difference in survival outcomewas also noted
at 5 years (37 vs. 57 %; p = 0.005). The small number of
complete 5 years follow-up for recipients was among the lim-
iting factors in this and other similar single center studies
published to date. Infectious complications were the predom-
inant cause for early deaths noted in this study. It also noted
the excess mortality for elderly recipients despite adjustment
for the Declining Exponential Approximation to Life
Expectancy (DEALE) in the older recipient group [23].
Vadnerker et al reviewed age-related complications in re-
cipient older than 65 years in 2011. A higher incidence of
malignancy and acute cellular rejection requiring augmented
immunosuppression was detected in this particular cohort
compared with the institutional experience of 60–65-year-
old recipients [25]. The associated editorial by Rahman et
Cahill points out that there was no detectable short-term sur-
vival difference in this recent cohort with an overall relatively
high rate of complications. The lack of disease-specific anal-
ysis and long-term survival of elderly recipients is apparent.
Case reports provide limited insight into current practice of
individual lung transplant programs. Shigemura et al. reported
lung transplantation for a single octogenarian with good early
outcome but concede that BA number of complicated issues
remain debatable, including ethical concerns…^ Clearly, the
appropriate allocation of suitable allografts as a scarce com-
modity remains a concern.
A more recent analysis of the ISHLT registry data com-
pared the median survival of recipients separated into five
age groups. The Kaplan–Meier survival curves provided to
show a marked separation after 12 months for recipients older
than 60 years old. There is a further attrition rate apparent
when comparing the subgroup older than 65 years old (n =
2014) with all other recipient age groups (age groups in years
<34, n = 6937; 35–49, n = 9477; 50–59, n = 13812; 60–65,
n = 7342). This represents the best registry evidence available
to guide transplant programs. The retrospective nature of the
analysis limits the value for individual case management, as it
does not adjust for other selection criteria. The precise impact
of age on prognostic value of lung transplantation would re-
quire prospective studies with surrogate markers for age-
related conditions in this context.
Donor age impact in lung transplantation
The dichotomy of the transplant process is evident when con-
sidering the donor-related circumstances. The prevalence of
pulmonary diseases among the ten leading causes of death
must be recognized. Ruling out pulmonary malignancy,
chronic obstructive airway disease and pneumonia may not
be simple in the donor setting. Furthermore, viral respiratory
tract infections have seasonal variation with higher prevalence
in senior donors with little clinical correlation available.
It is noteworthy that currently no regulatory restrictions are
imposed on acceptance of older donor lungs. Individual lung
transplant programs generally follow selection criteria proto-
cols. Current lung allocation systems do not incentivize pro-
curement of older donor lungs and utilization rates remain
low. Nevertheless, the impact of numerous donor parameters
has been studied to assess the possible impact on outcomes
after lung transplantation [26, 27]. The donor age variable
features in several retrospective analyses.
Satisfactory outcomes can be achieved with older lung
allografts, but the impact of age on physiologic changes of
lung function must be appreciated [15]. Decreased elasticity
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with resulting residual volume increase and vital capacity de-
creasemay be a concern. Such parameters and likely increased
A-a O2 gradients of older lungs may not be quantifiable in the
procurement situation. Potential chest wall stiffness and mus-
cle mass reduction of older donors, however, may not have a
clinically important impact on total lung capacity and maxi-
mum inspiratory pressures, as they arguably depend more on
the recipient’s condition in the peritransplant period.
In biological terms, the immunology of advanced age do-
nor lungs warrants some attention. The decline of adaptive
immune system function and the changed state of the innate
immune responses will affect the lung allograft. These chang-
es are not quantifiable in current routine procurement practice
but may render older allografts to higher susceptibility to par-
ticular respiratory tract infections and therefore increase risks
as inherited by the recipient [17]. Donors of advanced age
have been shown to express lower levels of interleukin-10
early after reperfusion. Cytokine gradients in turn are known
to correlate with the development of primary graft dysfunc-
tion. The risk of primary graft dysfunction in the absence of
rejection and cardiogenic issues or infective pathogens caus-
ing graft impairment has been studied.
Although early outcomes of utilization of older lungs have
been shown to be similar to those in recipients of lungs from
younger donors, late survival and the development of bron-
chiolitis obliterans syndrome have been negatively impacted.
There is currently no correlation of different donor age groups
to the various chronic lung allograft dysfunction (CLAD) phe-
notypes observed.
The influence of donor and recipient age in lung transplan-
tation was studied by Hayes et al. with a review of the United
Network of Organ Sharing (UNOS) SRTR registry data. There
is evidence that the number of older donor’s allografts being
utilized for transplantation is increasing [5]. Multivariate Cox
models applied to the large cohort demonstrated that donors
below 50 years of age or over reduced the recipients mortality
if less than 60 years old at time of transplantation. If, however,
the recipient was over the age of 65, only donors less than
50 years old decreased the risk for death after transplantation.
The primary finding was that older donor lungs appeared not to
affect survival when transplanted for older recipients but limit-
ed outcomes in Byounger recipients.^ Such data suggests that in
order to optimally utilize the donor pool, older donor lungs
should be used but some donor-recipient age matching should
be considered. This approach may potentially enhance long-
term outcomes in specific recipient age subgroups. It presents
an additional challenge in the complex matching of allografts.
After exclusion of significant functional impairment, and in
addition to serology, immunology, and size, age similarity in
older could be advocated in such recipients.
BAge-range matching^ allocation of older lung allografts
(>60 years old) may provide a pragmatic approach to increase
the utilization rate of these organs offered but frequently
rejected. A recently published Bfocus theme age^ in lung trans-
plantation analyzed the information available in the ISHLT reg-
istry. Two-thirds of recipients are aged 45–65 years, but the
trend for 60–69 years old and older than 70 years old is increas-
ing (see Fig. 3). Extremes of age in recipients confer an inde-
pendent risk factor for early death after transplants. The model
utilized in this retrospective analysis also demonstrates older
donor age to be an independent risk factor associated with mor-
tality after lung transplantation [20••].
Conclusions
Age will increasingly factor in the decision-making process
for lung transplant candidates. When considering patients for
the rigors of lung transplantation, life expectancy must not be
confused with individuals’ expectations in life. Frequently,
patients are seeking symptom relief and the known prognostic
limitations germane to lung transplantation may appear ac-
ceptable to older candidates. Informed consent obtained from
such candidates ought to include a specific benefit versus risk
discussion. For established subgroups of patients with end-
stage respiratory disease who have a reasonable survival ad-
vantage with transplantation, the systemic aspects inherent
with aging cannot be ignored.
The reported 1-year outcomes available from SRTR and
ISHLT registries are currently the best source of information
for generic decisions. Future analyses ought to further study
the impact of age on outcomes in lung transplantation. The
overriding concern, to allocate scarce lung allografts to the
most appropriate recipients, has to include the assessment of
the patient’s potential for full recovery, irrespective of
Bchronological^ age at the time of transplantation. Three-
year survival outcomes observed in the subpopulation
Fig. 3 Trends in lung transplantation over the period of 2000 to 2012 for
septuagenarians and sexagenarians in the USA, modified from Hayanga
et al. [24]
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transplanted at age 65 or older remain inferior to those ob-
served for younger age categories. Lungs from donors with
a chronological age of 45 and older can safely be transplanted,
but the stakes may be higher for such allografts especially in
combination with other extended donor criteria.
The advent of ex vivo lung perfusion systems (EVLP) may
allow for detailed differential assessment of older donor lungs.
This may lead to separation and selective use of Bgood old
lungs.^ Interventions aimed at regenerative or repair mecha-
nisms may be feasible to improve lung procurement to opti-
mize aged allografts.
A key concern remains who may be the most appropriate
recipient for any given organ to enhance outcomes. The
matching of older donors with advanced age recipients may
be a reasonable way of increasing utilization rates of such
allografts available. This may help to a modest extent to alle-
viate the lung allograft shortage and serve the increasingly
listed and carefully selected elderly candidates for lung
transplantation.
In light of the current evidence available, we advocate for
age matching of older donor lungs to optimize utilization with
a pragmatic approach.
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